Hematologic malignancies during pregnancy: A review

Hossam K. Mahmoud, Mohamed A. Samra, Gamal M. Fathy

Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt
Department of Hematology and BMT, Nasser Institute for Research and Treatment, Ministry of Health, Egypt

Abstract
Malignancy is the second most common cause of mortality in the reproductive period and it complicates up to one out of every 1000 pregnancies. When cancer is diagnosed during pregnancy, the management approach must take into consideration both the mother and her fetus. Hematologic cancers diagnosed in pregnancy are not common, resulting in paucity of randomized controlled trials. Diagnosis of such malignancies may be missed or delayed, as their symptoms are similar to those encountered during normal pregnancy. Also, many imaging studies may be hazardous during pregnancy. Management of these malignancies during pregnancy

Keywords: Hematologic malignancies; Pregnancy; Management; Diagnosis; Imaging studies.
Hosam K. Mahmoud received his Dr. med. habil Degree in Hematology from University of Essen, Germany, in 1986. He is a Professor of Hematology, at National Cancer Institute (NCI), Cairo University, since 1997. He was the President of Cairo University from August 2008 till June 2013. He received “Cairo university encouragement prize for medical science” (1990); “State recognition prize for advanced technological sciences serving the medical field” (2012); and “Medal of Science and Arts of the first class” (2013). His main fields of interest include hematology and bone marrow transplantation (BMT). He has published more than 100 papers in reputed international and local journals and participated in writing 6 books in hematology and BMT. He introduced the service of BMT for Egyptian patients for the first time in 1988 and since that time he led the NCI BMT team in performing allogeneic and autologous BMT for more than 4000 patients. He was elected as a member of the Advisory Board of the International Bone Marrow Transplantation Registry (IBMTR) for Africa and the Middle East in 1994. He was also serving in the ex-Chairman of the Egyptian Hemato-Oncology Group (EHOG). He is also a member of different national and international scientific societies including the following: International Society of Hematology (ISH), European Society for Blood and Marrow Transplantation (EBMT), Egyptian Society for Hematology (ESH), Egyptian Cancer Society (ECS), Egyptian Society of Hematology and Research (ESHRR), and Egyptian Foundation for Cancer Research (EFCR).

Gamal M. Fathy earned his MD degree in Clinical Hematology from Medical Research Institute, Alexandria University, in 2015. He is currently working as a Consultant of Hematology and BMT at Nasser Institute Hospital for Research and Treatment (NIHTR), Ministry of Health, Cairo, Egypt. He joined the Hematology and BMT Unit at NIHTR in March 2001, and since that time he participated in more than 2500 cases of allogeneic and autologous BMT as well as management of different malignant and benign hematologic diseases. He is also working as a trainer for hematology and BMT in the Egyptian Fellowship of Oncology. He participated in many international abstracts presented at the EBMT and the American Society for Blood and Marrow Transplantation (ASBMT) and two international papers. He is a member of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT) and The Egyptian Society of Hematology and Research (ESHRR).

Mohamed A. Samra obtained his MD degree from the National Cancer Institute (NCI), Cairo University, in 2002. He is a Professor of Medical Oncology at NCI, Cairo University, since 2013. His main fields of interests include hematology and bone marrow transplantation (BMT). He joined the NCI BMT team in 1995, and since that time he participated in performing allogeneic and autologous BMT for more than 3500 patients. Also, he has more than 20 years of experience in managing benign and malignant hematologic diseases as well as solid tumors. He has published more than 30 papers in peer-reviewed international and local journals and participated in more than 20 scientific abstracts and posters in international hematology and oncology conferences. He was the Secretary General of the Egyptian Hemato-Oncology Group (EHOG). He is also a member of different national and international scientific societies including the following: European Society of Medical Oncology (ESMO), European Hematology Association (EHA), American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), European Society for Blood and Marrow Transplantation (EBMT), Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT), and Egyptian Cancer Society (ECS).

Introduction

Having malignancy during pregnancy may put the patient and the treating physician in a very serious situation, as weighing the risk of cancer versus the lethal effect of the chemotherapy used for its treatment is a very tough issue. So it is very important to address whom, when, and how to treat those patients. That is to say treating physician should ask himself some questions. The first is whether this type and/or stage of the disease needs immediate intervention or treatment could be postponed till delivery. The second question is how can he treat this case during pregnancy using the safest road to reach a safe place, meaning that which type of chemotherapy would the mother tolerate and exert no or little side effects on the fetus during different trimesters of pregnancy.

Incidence

Cancer is diagnosed in approximately one out of 1000 pregnant women and this incidence is expected to grow due to the rising median age at pregnancy. The most common cancers associated with pregnancy are cervical (1:2;10000 pregnancies), breast cancer (1:3000–10000), melanoma (2.6:1000), lymphomas (1:1000–6000) and leukemias (1:75000–100000). Hematologic malignancies, which are considered to be diseases of old age, such as multiple myeloma (MM) and myeloproliferative neoplasms (MPNs), are recently more commonly encountered while the patients are pregnant owing to the rising median age at pregnancy, improved diagnostic molecular...
Hematological malignancies during pregnancy

Techniques used in MPNs and better overall survival (OS) in MM. On the other hand myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL) generally occur at an older age, so they are rarely diagnosed during pregnancy [1].

Diagnosis and staging of cancer during pregnancy

Several procedures are considered safe to be performed during any stage of pregnancy such as core needle or excisional biopsies and bone marrow (BM) biopsy [2].

Computed tomography (CT) scans and positron emission tomography (PET) scans should not be performed for staging of lymphoma during pregnancy due to the risk of radiation exposure of the fetus [3]. Ultrasonography can be safely used during pregnancy, while plain chest X-ray (CXR) can be performed, if required, in pregnant women with adequate abdominal shielding. Magnetic resonance imaging (MRI) should be avoided in the first trimester of pregnancy, while it can be performed during second and third trimesters if it is strongly indicated assuming that its results would significantly influence the management plan [4]. Gadolinium (a contrast medium used in MRI) should not be used in the first trimester, as it crosses the placenta and causes fetal malformations [5]. Gadolinium MRI scans can be used during second and third trimesters if strongly indicated [1].

Isotopic bone scans are generally not recommended during pregnancy unless there are no other means of detecting bone metastases and results would alter the treatment strategy. On the other hand, MRI has a specificity of 91% for the detection of bone metastases in hematologic cancers [6].

Acute leukemias

Acute leukemia (AL) developing during pregnancy necessitates a multidisciplinary team management including a medical oncologist, an obstetrician, and a neonatologist. It requires immediate management irrespective of the gestational age as any delay in therapy can seriously affect the prognosis of the mother [7]. Recommendations for management of these patients are hampered by the rarity of these conditions in pregnancy and insufficiency of available data in the literature. The largest experience of AL in pregnancy came from Mayo Clinic (1962–1999), where 17 cases of AL in pregnancy were treated [8]. Another retrospective study of 37 AL patients from 13 French centers was performed (1988–2003), in which vincristine, doxorubicin, daunorubicin, idarubicin, cytarabine, cyclophosphamide, asparaginase, mercaptopurine, prednisone, methotrexate, mitoxantrone, and all-trans-retinoic acid (ATRA) have been utilized during all trimesters [9]. In a review of 152 patients with ALL and AML, six neonates with congenital abnormalities, 12 with intrauterine growth retardation (IUGR), 11 fetal deaths, and 2 neonatal deaths were recorded [10].

Acute myeloid leukemia (AML)

The majority of cases with AML are diagnosed in the second or third trimesters. The standard regimen for induction consists of cytarabine and an anthracycline [11]. Exposure to cytarabine in the first trimester can cause severe limb malformations and its use is not advocated and termination is strongly preferred. In the second and third trimesters, it was associated with transient cytopenias, intrauterine fetal death, IUGR, and neonatal death from sepsis and gastrointestinal teritis [10].

Daunorubicin is the anthracycline of choice in pregnancy. Although rare cases of fetal cardiotoxicity have been documented with anthracycline use, fetal cardiac function should be monitored during pregnancy [12].

For relapsed AML, termination of pregnancy is highly recommended, because treatment usually requires high-dose chemotherapy, and BM transplantation, which cannot be given safely in pregnancy [13].

In summary, counseling and termination of pregnancy in first trimester are recommended. In second and third trimesters, induction chemotherapy with daunorubicin and cytarabine can be introduced, with regular surveillance for the development of congenital abnormalities and monitoring of fetal cardiac function.

Acute promyelocytic leukemia (APL)

The hematologic manifestations of APL, such as pancytopenia, disseminated intravascular coagulation and hyperfibrinolysis represent a medical emergency during pregnancy. Women with APL diagnosed during pregnancy have higher risks of abortion, perinatal mortality, IUGR, and preterm delivery [9]. Clinical sequelae include increased bleeding, infection, inflammation, placental abruption, and decreased oxygen and nutrient delivery [14]. APL is usually treated by ATRA combined with anthracycline-based chemotherapy (idarubicin or daunorubicin). It has a complete remission rate of >90% and a potential cure in up to 80%. During pregnancy, this drug regimen is controversial due to the potential teratogenic effects and medication-related complications such as fatal retinoic acid syndrome [15]. Retinoic acid in low doses is especially harmful to the fetus during weeks 3–5 of gestation. Complications that can result include craniofacial alterations, neural tube defects, cardiovascular malformations, and thymic aplasia [16]. However, the risk of teratogenic effects during the second and third trimesters of pregnancy is low [17].

In the first trimester, ATRA should be avoided, and women should be counseled to consider termination. Should termination of the pregnancy be unacceptable, treatment with an anthracycline should be started and ATRA introduced in the second trimester. Daunorubicin is the anthracycline of choice, not only because there is more experience of its use in pregnancy, but also because it may induce less fetal toxicity than idarubicin. Treatment after the beginning of the second trimester results in a more successful outcome. Chemotherapy does not appear to cause congenital abnormalities, but undoubtedly increases the risk of abortion, prematurity, low birth weight, neonatal neutropenia, and sepsis. Potentially, ATRA could be given alone with the addition of the anthracycline after delivery. This has resulted in remission rates equivalent to combination of ATRA and chemotherapy. However, using ATRA as a single agent increases the risk of ATRA syndrome (APL differentiation syndrome) and possible ATRA resistance. Alternatively, use of ATRA and an anthracycline is rec-
ommended for high-risk patients with hyperleukocytosis. Arsenic trioxide (ATO), which has been used for relapsed APL patients and more recently explored as first-line therapy, cannot be recommended at any stage of pregnancy as it is highly embryotoxic [13,16,17].

Acute lymphoblastic leukemia (ALL)

In a review by Terek et al. [18], 28% of leukemia cases diagnosed during pregnancy are ALL. In this study, a total of 17 patients with ALL received chemotherapy between gestational age of 15 and 33 weeks. Most chemotherapy regimens included anthracyclines, vincristine and steroids. About half of the women in this study achieved remission while the other half either relapsed or died from progression of the disease. Some infants were born with transient pancytopenia, respiratory distress and preterm delivery [18].

Before week 20 of gestation, termination should be considered, and then conventional therapy instituted. After the 20th week, bridging chemotherapy without methotrexate until the third trimester can be instituted. A brief period of treatment with prednisolone alone for 1–2 weeks may allow the patient to enter the period of gestation post 20 weeks in order to then receive more intensive chemotherapy. A similar approach with prednisolone alone can also be recommended for patients presenting close to 32 weeks of pregnancy. Methotrexate, an important drug in the treatment of ALL, should be avoided in first and second trimesters of pregnancy and may be used, if necessary, with caution in the third trimester [13].

Chronic myeloid leukemia (CML)

Recent use of BCR–ABL1 tyrosine kinase inhibitors (TKIs) has led to marked improvement of survival in CML patients. Many young female CML patients may become pregnant during their lifetime. It is important to mention that TKIs can inhibit several proteins, which are important for gonadal development, implantation and fetal development, thus increasing the risk of toxicities to the embryo. Imatinib is shown to be embryotoxic in animals with varying effects on fertility. As pregnancy is rare in CML, there are no randomized trials to address the optimal management of this disease. However, there are several case reports on CML in pregnancy [19].

Imatinib, the first TKI approved for the treatment of CML, has revolutionized the results of therapy with complete cytogenetic remission and OS rates of 82% and 90% respectively. However, almost one-third of patients need to be switched to another line of therapy due to resistance and/or intolerance to imatinib [20].Nilotinib, dasatinib, bosutinib and more recently ponatinib, are safe and efficient drugs for treatment of patients with chronic phase (CP) CML, who are imatinib intolerant or resistant [21–23].

As the lifespan of patients responding to different TKIs is prolonged, many women in reproductive period may seek medical advice for the possibility of further pregnancy. These women should be clearly informed about the risks of becoming pregnant while on therapy and the possibility of a loss of response after drug discontinuation to continue pregnancy. However, pregnancy can be planned with sustained optimal response to TKIs [24].

There is limited information about the use of second and third generation TKIs during pregnancy. Forty-five women have been reported of nilotinib exposure during pregnancy, with only one case of fetal abnormalities ending into pregnancy termination and another case of fetal death due to congenital transposition of great vessels [25]. Dasatinib should be used with much caution during pregnancy due to more potent and wider range of signaling pathway inhibition including platelet-derived growth factor receptor-α [26]. There are no available data regarding patients receiving bosutinib or ponatinib during pregnancy [25].

In a female patient in the childbearing period, effective contraception should be suggested at diagnosis. Conception should be only scheduled after achievement of a sustained major molecular response (MMR), or a deep molecular response (e.g. MR4.5) for at least 2 years. TKIs should be discontinued just before conception. TKIs should not be used during the period of fetal organ formation (weeks 5–13 of pregnancy). Quantitative Polymerase chain reaction (Q-PCR) tests for BCR/ABL: ABL ratio must be monitored every 1–2 months to assure the sustainability of molecular response. In case of hematologic or cytogenetic relapse, restarting treatment can be considered. Interferon (IFN) can be used safely throughout gestation [27]. Hydroxyurea may be considered to treat leukocytosis after fetal organogenesis [28]. Imatinib and nilotinib have limited placental transfer and can be used, if strongly indicated, after formation of placenta [29]. In contrast, dasatinib can pass extensively through the placenta, and it should not be used all through the pregnancy [30].

After labor, TKI therapy can be delayed to permit breast-feeding, only in case of stable molecular response. If it is important to restart therapy with TKI, breast milk is recommended during the first few postpartum days to deliver the colostrum to the baby [25].

Hazards of use of TKIs in pregnancy

Only few case reports of CML patients treated with TKIs during pregnancy are published. Most of these patients were treated with imatinib. In a study of 180 females treated with imatinib during pregnancy was performed, 50% of the patients delivered normal infants, and 28% underwent elective terminations (11% of them following identification of abnormalities). Abnormalities were identified in 12 infants with 9 of those defects occurring in the infants with known first trimester exposure to imatinib. In conclusion, most pregnancies exposed to imatinib are likely to have a successful outcome; however, there remains a risk that exposure may result in serious fetal malformations [31].

Fewer cases of exposure to newer TKIs during pregnancy have been also reported. One case of exposure to nilotinib during the first trimester was described in a patient who unexpectedly became pregnant while taking nilotinib until 7.4 weeks of pregnancy. Her baby was delivered without any congenital anomaly [32]. The outcome of pregnancy in 46 CML patients who received dasatinib while pregnant was recently reported. Live births occurred in 20 (43%) patients including 15 healthy and 5 abnormal infants with IUGR and/or premature delivery. Termination of pregnancy occurred in 26 (57%) patients (8 spontaneous and 18 elective). Seven pregnancies resulted in fetal and infant complications including 2 cases of hydrops...
fetalis, 2 cases of CNS abnormalities, and a case with renal tract abnormalities [33].

**Lymphoma**

Staging methods for lymphoma during pregnancy are limited only to CXR with protective shields for the abdomen, abdominopelvic US and BM biopsy. BM biopsy is recommended for patients with lymphoma especially those with systemic (B) symptoms, and/or peripheral blood cytopenias [34,35]. Laboratory workup should also include complete blood count, erythrocyte sedimentation rate, LDH, kidney function and liver function tests including serum alkaline phosphatase. However, the latter is highly elevated in the third trimester of pregnancy and may not be useful [36]. Abdominal disease can be also evaluated with non-contrast MRI [37,38]. In contrast, PET and gallium scans are not safe during pregnancy [39].

**Non-Hodgkin lymphoma (NHL)**

Pregnancy itself may produce symptoms similar to those of lymphoma leading to a significant delay in diagnosis of such patients and a higher frequency of advanced disease [40]. Also in pregnancy-associated NHL, there is a higher frequency of involvement of reproductive organs due to their increased blood flow and increased hormone receptor expression during pregnancy [41]. In a systematic review of pregnant women with NHL (no = 121), 91 (75%) patients had stage IV disease with involvement of reproductive organs (mostly the breast) seen in 49% of them [42].

**Indolent lymphoma**

Due to the nonaggressive nature of indolent lymphomas, their definitive therapy can be delayed until the second trimester of pregnancy, or even until delivery. Rituximab monotherapy can be given safely during the first trimester if there is an urgent need for treatment. R-CVP regimen (rituximab, cyclophosphamide, vincristine and prednisone) or R-CHOP regimen (R-CVP + doxorubicin) can be used during the second or third trimester, whereas fludarabine-based regimens are not recommended [42].

Bendamustine became the standard of care as frontline therapy in Western world. Bendamustine has been assigned to pregnancy category D by the US Food and Drug Admiration (FDA). Animal studies have revealed skeletal and visceral malformations, decreased fetal body weights, a significant increase in external and internal malformations, as well as embryo and fetal lethality. There are no controlled data in human pregnancy. Bendamustine should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

**Aggressive lymphomas**

Highly aggressive lymphomas (including diffuse large B-cell, mantle cell and mature T-cell lymphomas) diagnosed in pregnancy may be distinguished by an aggressive nature with worse prognosis due to delay in diagnosis, and insufficient therapy used. When adequate chemotherapy is given, prognosis of pregnant patients with NHL is similar to that of non-pregnant patients [40].

In the majority of patients with aggressive NHL diagnosed, during pregnancy, early therapy with chemotherapy combination regimens (such as CHOP) is usually needed. In the first trimester, the safety of CHOP protocol is not guaranteed and termination of pregnancy is usually advocated [40,43]. In some NHL patients with stage I/II disease with lower tumor burden, who are diagnosed in the first trimester, careful follow-up till the second trimester followed by proper chemoimmunotherapy may be indicated.

R-CHOP can be given more safely during the second or third trimester [40,43,44]. In a multicenter study, ninety pregnant women with aggressive lymphoma received the standard chemoimmunotherapy regimens in the second or third trimester of pregnancy with low frequency of maternal and fetal problems [41].

**Highly aggressive lymphomas**

As in aggressive lymphomas, the fulminant course and rapid progression of highly aggressive lymphomas such as lymphoblastic and Burkitt’s lymphomas nictitates prompt initiation of aggressive treatment. High-dose methotrexate, which is usually included in chemotherapeutic regimens for these lymphomas, is highly toxic to the embryo if used in first trimester. Thus, pregnancy termination is strongly advocated in such cases [45].

Although methotrexate use during the second and third trimesters may not be teratogenic, it is found to be associated with severe fetal myelosuppression [40].

**Rituximab during pregnancy**

Many case reports of rituximab use during pregnancy have been published, mainly for benign diseases and they did not show a higher risk of teratogenicity [46,47]. Use of rituximab for treatment of lymphoma in early pregnancy, may lead to a temporary fetal B-cells depletion, followed however with rapid recovery of B-cells [48].

Pregnancy outcomes were reported in a retrospective study of 153 pregnant patients exposed to rituximab. Live births were reported in ninety cases and the majority of them were not complicated. Neonatal complications included transient leucopenia with or without infections [49].

In conclusion, the beneficial value of rituximab therapy for aggressive lymphomas during the second or third trimester of gestation is greater than its hazards to the fetus. In the first trimester, rituximab use cannot be recommended, although the data on teratogenicity are limited.

**Hodgkin lymphoma (HL)**

ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine), the commonest chemotherapy regimen used for HL, should not be used during the first trimester, as information with respect to its safety is restricted. There are no available safety data regarding the use of other chemotherapeutic regimens used for treatment of HL such as “Stanford V” or “BEACOPP” during pregnancy.
Patients diagnosed with advanced HL at first trimester of gestation, should immediately receive chemotherapy with termination of pregnancy. Early-stage HL diagnosed in the first trimester could be closely observed for development of disease progression and begin chemotherapy in the second trimester. In some cases in first trimester, localized radiotherapy to cervical and/or axillary area with abdominal shielding is an option of therapy of HL [34,38,40,50].

Most pregnant women diagnosed with HL during the second and third trimesters can be managed with ABVD. In some cases diagnosed with localized stage (IA or IIA) disease in the late second or third trimester, chemotherapy can be postponed until after delivery allowing complete staging and selection of the proper therapy after labor. However, there are no randomized controlled trials comparing the results of early versus deferred therapy in such patients [38].

The 20-year survival rate of pregnant women with HL was similar to that of matched non-pregnant women with HL. In addition, the incidence of preterm delivery or IUGR was not higher in pregnant women with HL [51].

**Multiple Myeloma (MM)**

Pregnant patients diagnosed with symptomatic MM need prompt therapy. Immunomodulatory drugs such as thalidomide and lenalidomide may induce marked teratogenicity, and should be avoided during the whole pregnancy period [52]. Also, bortezomib cannot be recommended in pregnant patients, as there are few data about its safety.

Corticosteroids are the safest therapy of MM during pregnancy, and can be used as a monotherapy in patients with mildly symptomatic disease until delivery. In rapidly progressive disease, an intensive combination therapy is usually required. If this progressive disease is diagnosed in the first trimester, termination of pregnancy is recommended. If the patient has an extensive pelvic or vertebral bone disease, Cesarean section is preferred to avoid trauma resulting from vaginal delivery [14].

**Ph-negative myeloproliferative neoplasms (MPNs)**

Only limited data are available about polycythemia vera (PV) and essential thrombocythemia (ET) developing during pregnancy [53]. In these patients, there is an increased incidence of abortion (twice as normal), IUGR, and intrauterine death. Maternal complications occur in about 8% of patients [54,55].

Several factors may influence the therapeutic decision for PV/ET including disease-related and pregnancy-related features. High-risk pregnancy is defined by presence of any of the following factors: previous thrombosis/hemorrhage in the mother, previous pregnancy-related complications attributable to PV/ET, severe preeclampsia, abruptio placentae, and unexplained recurrent first trimester fetal loss, IUGR, intrauterine death [54]. The plasma volume starts to increase from the second trimester onward leading to reduction of hematocrit (Hct) and platelet count; then, these levels start to rise again after delivery leading to an increased thrombotic risk. Close monitoring by weekly blood counts is important during the first six weeks postpartum to detect rebound thrombocytosis or polycythemia [55].

In PV, it is recommended to maintain the Hct within the normal range of the contemporary trimester of pregnancy. In ET, low dose aspirin is safe and beneficial during pregnancy. In the absence of obvious contraindications, all PV and ET patients should receive aspirin 75 mg daily throughout gestation. From the day of delivery, aspirin is replaced by low molecular weight heparin (LMWH), for 6 weeks [55].

In high-risk pregnancy, LMWH is recommended throughout pregnancy and 6 weeks after labor. Cytoreductive therapy is indicated when the platelet level rises above >1000–1500 × 10^9/l or when cardiovascular risk factors are present. Hydroxyurea and anagrelide should be avoided due to their teratogenic effects. The drug of choice is non-pegylated IFN, as it has no teratogenic effects in animals or adverse effects in the small numbers of patients who receive this drug during pregnancy. Pegylated forms of IFN (PEG-IFN) are potentially less safe during pregnancy, as animal studies showed an adverse effect on the fetus while there are no adequate well-controlled studies in humans (pregnancy category C). So, PEG-IFN should be used only when benefit to the mother outweighs risk to their fetus. Breast-feeding is safe with LMWH, but contraindicated with all cytoreductive agents including IFN [56].

**Conclusions**

The prognosis of most pregnant women with hematologic malignancies is similar to that of matched nonpregnant women. Treatment strategy should put into consideration the severity of malignancy, the teratogenicity of available effective drugs and the necessity to continue pregnancy. During the first trimester, if chemotherapy is necessary, termination of pregnancy is generally indicated. The outcome of patients who receive chemotherapy in the second or third trimester is usually good.

**Conflict of interest**

The authors have declared no conflict of interest.

**Compliance with Ethics Requirements**

This article does not contain any studies with human or animal subjects.

**References**

[1] Pantheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N. Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):v266–73.
[2] Rovera F, Frattini F, Coglitore A, Marelli M, Rausci S, Dionigi G, et al. Breast cancer in pregnancy. Breast J 2010;16(Suppl. 1): S22–5.
[3] Austin LM, Frush DP. Compendium of national guidelines for imaging the pregnant patient. Am J Roentgenol 2011;197(4): W737–46.
[4] Bulas D, Egloff A. Benefits and risks of MRI in pregnancy. Semin Perinatol 2013;37(5):301–4.
[5] Muhler MR, Clement O, Salomon LJ, Balvay D, Autret G, Vayssettes C, et al. Maternofetal pharmacokinetics of a
Hematological malignancies during pregnancy

Gadolinium chelate contrast agent in mice. Radiology 2011;258(2):455–60.

Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 2009;70:393–400.

Iseminger KA, Lewis MA. Ethical challenges in treating mother and fetus when cancer complicates pregnancy. Obstet Gynecol Clin North Am 1998;25:273–85.

Greenlund LJ, Letendre L, Telfer A. Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk Lymphoma 2001;41(5–6):571–7.

Chelghoum Y, Vey N, Raffoux E, Huguet F, Pigneaux A, Witz B, et al. Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer 2005;104:110–7.

Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283–91.

Caligiuri MA, Mayer RJ. Pregnancy and leukemia. Semin Oncol 1989;16:388–96.

Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004;15:146–50.

Shapira T, Pereg D, Lishner M. How I treat acute and chronic leukemia in pregnancy. Blood Rev 2008;22(5):247–59.

Rizack T, Mega A, Legare R, Castillo J. Management of hematological malignancies during pregnancy. A J Hematol 2009;84(12):830–41.

Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, et al. Long-term follow-up confirms the benefits of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000;14(8):1371–7.

Valappil S, Kurkac M, Howell R. Outcome of pregnancy in women treated with all-trans retinoic acid; a case report and review of literature. Hematology 2007;12(5):415–8.

Consoli U, Figuera A, Milone G, Meli CR, Guido G, Indelicato P, et al. Antitumor effect of all-trans retinoic acid on chronic myelogenous leukemia in pregnancy. Anticancer Res 2015;35(1):1–15.

Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International Randomized Study of Interferon Vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. In: 51st ASH annual meeting and exposition; New Orleans (LA). December 5–8, 2009: abstract 1126.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561–6.

Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23(6):1054–61.

Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27(1):107–12.

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European leukemia net recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122(6):872–84.

Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 2014;6(1):e2014028.

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305(5682):399–401.

Pons JC, Lebon P, Frydman R, Delfraissy JF. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995;10(1):7–10.

Patel M, Dakes IA, Hull JC. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. Am J Obstet Gynecol 1991;165(3):565–6.

Webb MJ, Jafda D. Imatinib use in pregnancy. Turk J Haematol 2012;29(4):405–8.

Beverlile P, Andreoli A, Mir O, Anselem O, Delezoide AL, Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs 2012;23(7):754–7.

Pye S, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood 2008;111(12):5505–8.

Conchon M, Sanabani S, Bendit I, Santos, Serpa M, Dorliac-Llacar P. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 2009;2:42.

Cortes J, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley J. The impact of dasatinib on pregnancy outcomes. Am J Hematol 2015;90(12):1111–5.

Weisz B, Meirow D, Schiff E, Lishner M. Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther 2004;4(5):889–902.

Cohen-Kerem R, Raillon C, Oren D, Lishner M, Koren G. Pregnancy outcome following non-obstetric surgical intervention. Am J Surg 2003;190(3):467–73.

Pereg D, Koren G, Lishner M. The treatment of Hodgkin’s and non-Hodgkin’s lymphoma in pregnancy. Haematologica 2007;92(9):1230–7.

Kawabata I, Takahashi Y, Iwagaki S, Tamaya T. MRI during pregnancy. J Perinat Med 2003;31(6):449–58.

Levine D. Obstetric MRI. J Magn Reson Imaging 2006;24(1):1–15.

Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. J Nucl Med 2001;42(8):1238–42.

Koren G, Lishner M, Santiago S, editors. The Motherisk guide to pregnancy and lactation. Canada: Motherisk Program Toronto; 2005.

Evans AM, Advani R, Press OW Losso IS, Vose JM, Hernandez-Illuziturri FJ, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 2013;31(32):4132–9.

Horowitz NA, Benyamini N, Wohlhart K, Brenner B, Avivi I. Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review. Lancet Oncol 2013;14(7):e275–82.

Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001;2(3):173–7.

Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999;17(3):855–61.

Terathanasia Warkany J. Teratology 1978;17(2):187–92.

Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006;26(4):252–5.
[47] Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004;72(4):292–5.

[48] Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006;91(10):1426–7.

[49] Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011;117(5):1499–506.

[50] Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur J Cancer 2006;42(2):126–40.

[51] Lishner M, Zemlickis D, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Maternal and foetal outcome following Hodgkin’s disease in pregnancy. Br J Cancer 1992;65(1):114–7.

[52] Bwire R, Freeman J, Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opin Drug Saf 2011;10(1):3–8.

[53] Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 2006;32(4):422–9.

[54] Barbui T, Finaazzi G. Special issues in myeloproliferative neoplasms. Curr Hematol Malig Rep 2011;6(1):28–35.

[55] Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am 2011;25(2):261–75.

[56] McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005;130(2):174–95.